Skip to main content

Table 3 Adverse events before and after schedule modification

From: Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases

No. 25 mg, 4/2 schedule 25 mg, 2/1 schedule
  Grade 2 Grade 3 Grade 2 Grade 3
1 Fatigue, emesis, leukopenia, neutropenia None Emesis, neutropenia None
2 Fatigue, anorexia, dysgeusia, neutropenia, hand-foot syndrome None Fatigue, anorexia, dysgeusia, hand-foot syndrome None
3 - - Neutropenia None
4 Fatigue, dysgeusia Proteinuria Diarrhea Proteinuria
5 Neutropenia None None None
6 Anorexia Fatigue, mucositis, neutropenia Fatigue Neutropenia
  1. 25 mg of sunitinib was administrated on 3/1schedule, instead of 4/2 schedule.